Prevention of manifestations of atherothrombosis in adults: in patients with myocardial infarction (start of treatment - a few days after onset, but no later than in 35 days), ischemic stroke (start of treatment - in 7 days, but no later than 6 months after onset), or who have been diagnosed with peripheral arterial disease (arterial disease and atherothrombosis of the vessels of the lower extremities); in patients with acute coronary syndrome: with acute coronary syndrome without ST segment elevation (unstable angina pectoris or myocardial infarction without Q wave), including in patients who had a stent during percutaneous coronary angioplasty, in combination with acetylsalicylic acid (ASA) with acute myocardial infarction with ST segment elevation in combination with acetylsalicylic acid (in patients receiving standard medical treatment and for whom thrombolytic therapy is indicated). Prevention of atherothrombotic and thromboembolic events in atrial fibrillation. Clopidogrel in combination with ASA is indicated for adult patients with atrial fibrillation who have at least one risk factor for vascular events, who have contraindications to treatment with vitamin K antagonists (VKA) and who have a low risk of bleeding, for the prevention of atherothrombotic and thromboembolic events, including a stroke.